Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
63.24 ^USD	-0.46%		+0.03%	-14.52%

Apr. 17	Exact Sciences Corporation announced that it has received $266.75 million in funding	CI
Apr. 15	Sector Update: Health Care Stocks Advance Premarket Monday	MT

Exact Sciences : announces appointment of John A. Fallon, M.D., to company's board of directors

January 25, 2016 at 08:49 am EST

01/11/2016

Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results

104,000 Cologuard® tests completed with compliance rate exceeding 70 percent during launch year MADISON, Wis. , Jan.11, 2016 /PRNewswire/ - Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company completed approximately 38,000 Cologuard tests during the fourth quarter ended Dec. 31, 2015 , generating approximately $14.0 million to $14.5 million in revenue. For the full year 2015, the company expects revenue to be approximately $39.0 million to $39.5 million , the result of completin...

EXACT Sciences Corporation issued this content on 25 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 25 January 2016 13:48:30 UTC

Original Document: http://investor.exactsciences.com/releasedetail.cfm?ReleaseID=951496

Latest news about Exact Sciences Corporation

Exact Sciences Corporation announced that it has received $266.75 million in funding	Apr. 16	CI
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Exact Sciences Names Aaron Bloomer CFO	Apr. 15	MT
Exact Sciences Appoints Aaron Bloomer as Chief Financial Officer, Effective from May 15, 2024	Apr. 15	CI
Exact Sciences Corporation Announces Executive Changes	Apr. 15	CI
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes	Apr. 11	MT
Exact Sciences Corporation announced that it expects to receive $266.8 million in funding	Apr. 09	CI
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer	Mar. 28	CI
Transcript : Exact Sciences Corporation - Special Call	Mar. 14
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing	Mar. 05	MT
Transcript : Exact Sciences Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM	Mar. 04
Exact Sciences Insider Sold Shares Worth $356,302, According to a Recent SEC Filing	Feb. 29	MT
Exact Sciences Insider Sold Shares Worth $305,963, According to a Recent SEC Filing	Feb. 23	MT
Transcript : Exact Sciences Corporation, Q4 2023 Earnings Call, Feb 21, 2024	Feb. 21
Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $646.9M, vs. Street Est of $639.7M	Feb. 21	MT
Exact Sciences Corporation Provides Earnings Guidance for the first quarter and Year 2024	Feb. 21	CI
Exact Sciences' Q4 Loss Narrows, Revenue Increases; Sets 2024 Revenue Forecast	Feb. 21	MT
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI
Transcript : Exact Sciences Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM	Jan. 08
Exact Sciences Sees 17% Growth in Q4 Revenue	Jan. 08	MT
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024	Jan. 07	CI
Exact Sciences Corporation Provides Revenue Guidance for the Year Ended December 31, 2023 and 2024	Jan. 07	CI
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Executive Vice President	Jan. 07	CI
Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91	Jan. 02	MT
Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients	Dec. 01	CI

Chart Exact Sciences Corporation

Duration

Period

More charts

Company Profile

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Companyâs products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Companyâs flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patientâs breast tumor tissue.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Exact Sciences Corporation

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

63.24 USD

Average target price

89.37 USD

Spread / Average Target

+41.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
EXACT SCIENCES CORPORATION	-14.52%	11.48B
IOVANCE BIOTHERAPEUTICS, INC.	+44.03%	3.27B
GUARDANT HEALTH, INC.	-33.09%	2.2B
BGI GENOMICS CO., LTD.	-18.60%	2.05B
VERACYTE, INC.	-27.59%	1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+17.10%	1.01B
SEEGENE, INC.	-3.06%	743M
CAREDX, INC	-33.50%	413M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.94%	377M
CURIOX BIOSYSTEMS CO., LTD	+27.44%	374M

Bio Diagnostics & Testing